ZA200902187B - 8-Ethinylxanthine derivatives as selective A2A receptor antagonists - Google Patents

8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Info

Publication number
ZA200902187B
ZA200902187B ZA200902187A ZA200902187A ZA200902187B ZA 200902187 B ZA200902187 B ZA 200902187B ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 A ZA200902187 A ZA 200902187A ZA 200902187 B ZA200902187 B ZA 200902187B
Authority
ZA
South Africa
Prior art keywords
ethinylxanthine
selective
derivatives
receptor antagonists
antagonists
Prior art date
Application number
ZA200902187A
Other languages
English (en)
Inventor
Mueller Christa
Hockemeyer Joerg
Tzvetkov Nikolay
Burbiel Joachim
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of ZA200902187B publication Critical patent/ZA200902187B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200902187A 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists ZA200902187B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026739A EP1939197A1 (en) 2006-12-22 2006-12-22 8-ethinylxanthine derivatives as selective A2A receptor antagonists

Publications (1)

Publication Number Publication Date
ZA200902187B true ZA200902187B (en) 2009-11-25

Family

ID=37733427

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902187A ZA200902187B (en) 2006-12-22 2009-03-26 8-Ethinylxanthine derivatives as selective A2A receptor antagonists

Country Status (12)

Country Link
US (1) US8044061B2 (xx)
EP (2) EP1939197A1 (xx)
CN (1) CN101631788A (xx)
AR (1) AR064657A1 (xx)
AU (1) AU2007338413A1 (xx)
BR (1) BRPI0720419A2 (xx)
CA (1) CA2672692A1 (xx)
CO (1) CO6210727A2 (xx)
RU (1) RU2009127883A (xx)
UY (1) UY30835A1 (xx)
WO (1) WO2008077557A1 (xx)
ZA (1) ZA200902187B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
EP2465859A1 (en) 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
US9221821B2 (en) * 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
GB201311107D0 (en) * 2013-06-21 2013-08-07 Univ Edinburgh Bioorthogonal methods and compounds
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
GB2553684B (en) * 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
GB2553685B (en) * 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
GB2553686B (en) * 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
MX2017012568A (es) 2015-03-31 2018-01-25 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
BR112017021386A2 (pt) * 2015-04-08 2018-07-03 Lewis And Clark Pharmaceuticals, Inc. carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b.
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
MA52093A (fr) 2018-03-19 2021-01-27 Taiho Pharmaceutical Co Ltd Composition pharmaceutique comprenant du sulfate d'alkyle de sodium
US20240002416A1 (en) 2020-10-15 2024-01-04 Rheinische-Friedrich-Wilhelms-Universität Bonn MRGPRX4 Agonists and Antagonists
CN115636831A (zh) * 2022-10-27 2023-01-24 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
EP0698607B1 (en) 1994-02-23 2002-05-29 Kyowa Hakko Kogyo Kabushiki Kaisha Xanthine derivative
CA2369981A1 (en) 1999-04-09 2000-10-19 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
BR0207216A (pt) 2001-02-14 2004-03-09 Warner Lambert Co Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz
DK1368349T3 (da) * 2001-02-24 2007-05-21 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
AU2005231440B9 (en) 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines

Also Published As

Publication number Publication date
AU2007338413A1 (en) 2008-07-03
UY30835A1 (es) 2008-07-31
CO6210727A2 (es) 2010-10-20
AR064657A1 (es) 2009-04-15
US20080221134A1 (en) 2008-09-11
WO2008077557A1 (en) 2008-07-03
US8044061B2 (en) 2011-10-25
EP2097415A1 (en) 2009-09-09
BRPI0720419A2 (pt) 2013-12-31
EP2097415B1 (en) 2014-10-29
CN101631788A (zh) 2010-01-20
CA2672692A1 (en) 2008-07-03
RU2009127883A (ru) 2011-01-27
EP1939197A1 (en) 2008-07-02
WO2008077557A8 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
ZA200901036B (en) Adenosine derivatives as A2A receptor agonists
IL201234A0 (en) Adenosine a2a receptor antagonists
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
IL194398A0 (en) Bisadenosine compounds as adenosine a2a receptor agonists
HK1136302A1 (en) Progesterone receptor antagonists
EP2032797A4 (en) ADENOSINE A2B RECEPTOR ANTAGONISTS
PL2069310T3 (pl) Pochodne sulfonylopirazolino-1-karboksyamidyny jako antagoniści 5-HT6
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
PL1912976T3 (pl) Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
HUP0501169A2 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
GB0605861D0 (en) A2B adenosine receptor antagonists
GB0705379D0 (en) A2b adenosine receptor antagonists
GB0505786D0 (en) A2b adenosine receptor antagonists
ZA200603486B (en) Arylindenopyridines and arylindenopyridines and their use as adenosine A2a receptor antagonist
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists